Form 4: LAVA Therapeutics Director Peter Kiener Acquires Options
SEC Form 4 Filing
Director Peter Kiener reports acquisition of options to purchase 33,390 common shares of LAVA Therapeutics NV.
Summary
- Peter Kiener, a director of LAVA Therapeutics NV, filed a Form 4 on February 18, 2025, reporting a transaction that occurred on February 13, 2025.
- Kiener acquired options to purchase 33,390 common shares at an exercise price of $0.93.
- These options vest on February 13, 2026, contingent upon continued service with the Issuer.
- Following the transaction, Kiener directly owns 33,390 common shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of options by a director may signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of transaction: Peter Kiener acquired options to purchase common shares. |
| 02/13/2026 | Vesting date for the options, contingent upon continued service. |
| 02/12/2035 | Expiration date of the options. |
| 02/18/2025 | Date of Form 4 filing. |
Keywords
Form 4, LAVA Therapeutics, Director, Peter Kiener, Options, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.